The European Medicines Agency granted orphan drug designation to PIQUR's lead compound PQR309 for the treatment of patients with diffuse large B-cell lymphoma.
The Addario Lung Cancer Medical Institute and Biocept Inc. announced a clinical collaboration and initiation of the landmark ALCMI-009 liquid biopsy clinical trial, which was developed and will be conducted by ALCMI and its consortium of leading U.S. and international oncology centers.
EpiThany, Merck KGaA, Pfizer to evaluate combination of avelumab and EP-101 STEMVAC in breast cancer
EpiThany today announced that they have entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate avelumab*, a human anti-PD-L1 antibody, and EP-101 STEMVAC, a multi-antigen, polyepitope vaccine, in a phase II trial in women with breast cancer.
Array BioPharma Inc. announced it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada) to investigate the safety and efficacy of Array's MEK inhibitor, binimetinib, with Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), in metastatic colorectal cancer patients with microsatellite stable tumors.
OncoSec Medical Inc. has entered a clinical trial collaboration and supply agreement with Merck to evaluate the combination of OncoSec's ImmuoPulse IL-12 with Merck's anti-PD-1 therapy Keytruda (pembrolizumab) in a phase II clinical trial, referred to as PISCES.
Regeneron Pharmaceuticals Inc. and SillaJen Inc. announced a clinical and supply agreement for a phase Ib dose-escalation study in renal cell carcinoma.
Regeneron Pharmaceuticals Inc. and Inovio Pharmaceuticals Inc. announced a clinical study agreement for a Phase Ib/IIa immuno-oncology trial.
Robert Vonderheide, an expert in cancer immunotherapy and translational research, was named director of the Abramson Cancer Center of the University of Pennsylvania.
The Pershing Square Sohn Cancer Research Alliance announced the six winners of the fourth annual Pershing Square Sohn Prize for Young Investigators in Cancer Research, awarded annually to promising early career, NYC-area scientists.
The Andrew Sabin Family Fellowship Program provides $100,000 in funding per fellow over two years through a $30 million endowed gift by the Andrew Sabin Family Foundation to encourage research creativity, independent thinking and high-impact cancer research.
